Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiromichi Wakui, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2024
Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiroshi Takeda, Hisashi Yokomizo, et al. Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Frontiers in Pharmacology. 2024. 15
Naoki Sakane, Yushi Hirota, Akane Yamamoto, Junnosuke Miura, Hiroko Takaike, Sari Hoshina, Masao Toyoda, Nobumichi Saito, Kiminori Hosoda, Masaki Matsubara, et al. Association of scan frequency with CGM-derived metrics and influential factors in adults with type 1 diabetes mellitus. Diabetology international. 2024. 15. 1. 109-116
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Shunichiro Tsukamoto, Moritsugu Kimura, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Tomohiko Kanaoka, Togo Aoyama, et al. The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists. Cardiovascular endocrinology & metabolism. 2023. 12. 4. e0292